Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on EKSO BIONICS (EKSO – Research Report). The associated price target remains the same with $9.00.
Swayampakula Ramakanth’s rating is based on Ekso Bionics’ strategic initiatives and financial outlook. The company has recently formed partnerships aimed at expanding the reach of its Indego Personal product and simplifying the reimbursement process. These collaborations are expected to broaden market access and potentially drive significant revenue growth starting in 2025. Additionally, despite a slight decline in revenue for 2024, the company anticipates growth in both its traditional enterprise business and the Indego Personal segment in the coming year.
Ramakanth also considers the company’s financial health and valuation in his assessment. Ekso Bionics ended the year with a solid cash position, which is deemed sufficient to support its operations. The analyst’s price target of $9 per share is derived from a combination of valuation methods, including projected future revenues and earnings. While there are inherent risks such as commercial and regulatory challenges, the overall outlook for Ekso Bionics appears promising, justifying the Buy rating.